PMID- 19128465
OWN - NLM
STAT- MEDLINE
DCOM- 20090324
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 9
DP  - 2009 Jan 7
TI  - Evaluation of gene amplification and protein expression of HER-2/neu in 
      esophageal squamous cell carcinoma using Fluorescence in situ Hybridization 
      (FISH) and immunohistochemistry.
PG  - 6
LID - 10.1186/1471-2407-9-6 [doi]
AB  - BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is the sixth most frequent 
      neoplasia in Brazil. It is usually associated with a poor prognosis because it is 
      often at an advanced stage when diagnosed and there is a high frequency of lymph 
      node metastases. It is important to know what prognostic factors can facilitate 
      diagnosis, optimize therapeutic decisions, and improve the survival of these 
      patients. A member of the epidermal growth factor receptor (EGFR) family, 
      c-erbB-2, has received much attention because of its therapeutic implications; 
      however, few studies involving fluorescence in situ hybridization (FISH) analysis 
      of HER-2/neu gene amplification and protein expression in ESCC have been 
      conducted. The aim of this study was to verify the presence of HER-2/neu gene 
      amplification using FISH, and to correlate the results with immunohistochemical 
      expression and clinical-pathological findings. METHODS: One hundred and 
      ninety-nine ESCC cases were evaluated using the Tissue Microarray (TMA) 
      technique. A polyclonal antibody against c-erbB-2 was used for 
      immunohistochemistry. Analyses were based on the membrane staining pattern. The 
      results were classified according to the Herceptest criteria (DAKO): negative 
      (0/1+), potential positive (2+) and positive (3+). The FISH reactions were 
      performed according to the FISH HER2 PharmDx (DAKO) protocol. In each case, 100 
      tumor nuclei were evaluated. Cases showing a gene/CEN17 fluorescence ratio > or = 
      2 were considered positive for gene amplification. RESULTS: The c-erbB-2 
      expression was negative in 117/185 cases (63.2%) and positive in 68 (36.8%), of 
      which 56 (30.3%) were 2+ and 12 (6.5%) were 3+. No significant associations were 
      found among protein expression, clinicopathological data and overall survival. 
      Among the 47 cases analyzed, 38 (80.9%) showed no gene amplification while 9 
      (19.1%) showed amplification, as demonstrated by FISH. Cases that were negative 
      (0/1+) and potential positive (2+) for c-erbB-2 expression by 
      immunohistochemistry showed no gene amplification. However, all cases with gene 
      amplification were positive (3+) by immunohistochemistry. According to univariate 
      analysis, there was a significant difference (p = 0.003) in survival rates when 
      cases with and without HER-2/neu amplification were compared. CONCLUSION: Our 
      data demonstrate the correspondence between gene amplification and protein 
      expression of HER-2/neu. Gene amplification is an indicator of poor prognosis in 
      ESCC.
FAU - Sato-Kuwabara, Yukie
AU  - Sato-Kuwabara Y
AD  - Department of Anatomic Pathology, Hospital AC Camargo, Sao Paulo, SP, Brazil. 
      yukiesato@gmail.com
FAU - Neves, Jose I
AU  - Neves JI
FAU - Fregnani, Jose H T G
AU  - Fregnani JH
FAU - Sallum, Rubens A
AU  - Sallum RA
FAU - Soares, Fernando A
AU  - Soares FA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090107
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics/metabolism/mortality
MH  - Esophageal Neoplasms/diagnosis/*genetics/metabolism/mortality
MH  - Female
MH  - *Gene Amplification
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Survival Rate
PMC - PMC2648997
EDAT- 2009/01/09 09:00
MHDA- 2009/03/25 09:00
PMCR- 2009/01/07
CRDT- 2009/01/09 09:00
PHST- 2008/03/12 00:00 [received]
PHST- 2009/01/07 00:00 [accepted]
PHST- 2009/01/09 09:00 [entrez]
PHST- 2009/01/09 09:00 [pubmed]
PHST- 2009/03/25 09:00 [medline]
PHST- 2009/01/07 00:00 [pmc-release]
AID - 1471-2407-9-6 [pii]
AID - 10.1186/1471-2407-9-6 [doi]
PST - epublish
SO  - BMC Cancer. 2009 Jan 7;9:6. doi: 10.1186/1471-2407-9-6.